1. Home
  2. ACET vs SPCB Comparison

ACET vs SPCB Comparison

Compare ACET & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • SPCB
  • Stock Information
  • Founded
  • ACET 1947
  • SPCB 1988
  • Country
  • ACET United States
  • SPCB Israel
  • Employees
  • ACET N/A
  • SPCB N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • SPCB Semiconductors
  • Sector
  • ACET Health Care
  • SPCB Technology
  • Exchange
  • ACET Nasdaq
  • SPCB Nasdaq
  • Market Cap
  • ACET 64.9M
  • SPCB 53.3M
  • IPO Year
  • ACET N/A
  • SPCB N/A
  • Fundamental
  • Price
  • ACET $0.61
  • SPCB $9.72
  • Analyst Decision
  • ACET Buy
  • SPCB Strong Buy
  • Analyst Count
  • ACET 6
  • SPCB 1
  • Target Price
  • ACET $6.00
  • SPCB $18.00
  • AVG Volume (30 Days)
  • ACET 398.4K
  • SPCB 166.8K
  • Earning Date
  • ACET 08-12-2025
  • SPCB 08-14-2025
  • Dividend Yield
  • ACET N/A
  • SPCB N/A
  • EPS Growth
  • ACET N/A
  • SPCB N/A
  • EPS
  • ACET N/A
  • SPCB 1.89
  • Revenue
  • ACET N/A
  • SPCB $27,831,000.00
  • Revenue This Year
  • ACET N/A
  • SPCB $2.73
  • Revenue Next Year
  • ACET N/A
  • SPCB $22.87
  • P/E Ratio
  • ACET N/A
  • SPCB $5.16
  • Revenue Growth
  • ACET N/A
  • SPCB 2.90
  • 52 Week Low
  • ACET $0.45
  • SPCB $2.55
  • 52 Week High
  • ACET $1.70
  • SPCB $18.95
  • Technical
  • Relative Strength Index (RSI)
  • ACET 38.76
  • SPCB 47.89
  • Support Level
  • ACET $0.61
  • SPCB $9.61
  • Resistance Level
  • ACET $0.69
  • SPCB $11.14
  • Average True Range (ATR)
  • ACET 0.04
  • SPCB 0.68
  • MACD
  • ACET -0.01
  • SPCB -0.22
  • Stochastic Oscillator
  • ACET 12.80
  • SPCB 17.44

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

Share on Social Networks: